Group I mGluR regulates the polarity of spike-timing dependent plasticity in substantia gelatinosa neurons.
The spinal synaptic plasticity is associated with a central sensitization of nociceptive input, which accounts for the generation of hyperalgesia in chronic pain. However, how group I metabotropic glutamate receptors (mGluRs) may operate spinal plasticity remains essentially unexplored. Here, we have identified spike-timing dependent synaptic plasticity in substantia gelatinosa (SG) neurons, using perforated patch-clamp recordings of SG neuron in a spinal cord slice preparation. In the presence of bicuculline and strychnine, long-term potentiation (LTP) was blocked by AP-5 and Ca2+ chelator BAPTA-AM. The group I mGluR antagonist AIDA, PLC inhibitor U-73122, and IP3 receptor blocker 2-APB shifted LTP to long-term depression (LTD) without affecting acute synaptic transmission. These findings provide a link between postsynaptic group I mGluR/PLC/IP3-gated Ca2+ store regulating the polarity of synaptic plasticity and spinal central sensitization.
Jung
Sung Jun
SJ
Department of Physiology, Kangwon National University College of Medicine, Chuncheon 200-701, Republic of Korea.
Kim
Sang Jeong
SJ
Park
Yun Kyung
YK
Oh
Seog Bae
SB
Cho
Kwangwook
K
Kim
Jun
J
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D001896:Boron Compounds / Q000494:pharmacology; D002118:Calcium / Q000037:antagonists & inhibitors / Q000378:metabolism; D015220:Calcium Channels; D002614:Chelating Agents / Q000494:pharmacology; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004963:Estrenes / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005260:Female; D007189:Indans / Q000494:pharmacology; D053496:Inositol 1,4,5-Trisphosphate Receptors; D017774:Long-Term Potentiation / Q000187:drug effects / Q000502:physiology; D036881:Long-Term Synaptic Depression / Q000187:drug effects / Q000502:physiology; D008297:Male; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D011760:Pyrrolidinones / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000502:physiology*; D019311:Staurosporine / Q000494:pharmacology; D013376:Substantia Gelatinosa / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors
C095756:1-aminoindan-1,5-dicarboxylic acid; D001896:Boron Compounds; D015220:Calcium Channels; D002614:Chelating Agents; D004963:Estrenes; D018691:Excitatory Amino Acid Antagonists; D007189:Indans; D053496:Inositol 1,4,5-Trisphosphate Receptors; D011760:Pyrrolidinones; D018160:Receptors, Cytoplasmic and Nuclear; D018094:Receptors, Metabotropic Glutamate; C104077:metabotropic glutamate receptor type 1; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D004533:Egtazic Acid; D015763:2-Amino-5-phosphonovalerate; C109986:2-aminoethoxydiphenyl borate; D010738:Type C Phospholipases; D019311:Staurosporine; D002118:Calcium